A Phase Ic, Open-Label, Multicenter Study to Evaluate the Safety, Tolerability, and Activity of Inhaled GDC-6988 in Patients With Muco-Obstructive Disease
Latest Information Update: 01 Oct 2024
At a glance
- Drugs ETD 002 (Primary)
- Indications Chronic obstructive pulmonary disease; Cystic fibrosis
- Focus Adverse reactions
- Sponsors Genentech
- 01 Oct 2024 New trial record